<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34286338</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1745-1701</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jan</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Schizophrenia bulletin</Title>
          <ISOAbbreviation>Schizophr Bull</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.</ArticleTitle>
        <Pagination>
          <StartPage>166</StartPage>
          <EndPage>175</EndPage>
          <MedlinePgn>166-175</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbab087</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">People with schizophrenia/schizoaffective disorder (schizophrenia) die early, largely due to cardiovascular-related mortality. Antipsychotics are associated with lower mortality. We aimed to explore whether antipsychotic use can reduce discontinuation of medications for cardiovascular risk factors and diseases ("cardiometacolic drugs"), using a within-study design controlling for subject-related factors.</AbstractText>
          <AbstractText Label="METHODS">Persons diagnosed with schizophrenia between 1972 and 2014, aged &lt;65 years at cohort entry were identified in Finnish national databases. Four subcohorts were formed based on cardiometabolic drug use during the follow-up period, 1996-2017, namely statin (n = 14,047), antidiabetic (n = 13,070), antihypertensive (n = 17,227), and beta-blocker (n = 21,464) users. To control for subject-related factors, including likelihood of adherence as a trait characteristic, we conducted a within-subject study comparing the risk of discontinuation of each cardiometabolic drug during periods on vs off antipsychotics within each subject. We also accounted for number of psychiatric and nonpsychiatric visits in sensitivity analyses.</AbstractText>
          <AbstractText Label="RESULTS">In 52,607 subjects with schizophrenia, any antipsychotic use vs nonuse was associated with decreased discontinuation risk of antidiabetics (adjusted hazard ratio [aHR] = 0.56, 95% confidence interval [CI] = 0.47-0.66), statins (aHR = 0.61, 95%CI = 0.53-0.70), antihypertensives (aHR = 0.63, 95%CI = 0.56-0.71), and beta-blockers (aHR = 0.79, 95%CI = 0.73-0.87). Antipsychotics ranking best for discontinuation of all cardiometabolic drug categories were clozapine (aHR range = 0.34-0.55), followed by olanzapine (aHR = 0.43-0.71). For statins, aHRs ranged from aHR = 0.30 (95%CI = 0.09-0.98) (flupentixol-long-acting injectable (LAI) to aHR = 0.71 (95%CI = 0.52-0.97) (risperidone-LAI), for anti-diabetic medications from aHR = 0.37 (95%CI = 0.28-0.50) (clozapine) to aHR = 0.70 (95%CI = 0.53-0.92) (quetiapine), for antihypertensives from aHR = 0.14 (95%CI = 0.04-0.46) (paliperidone-LAI) to aHR = 0.69 (95%CI = 0.54-0.88) (perphenazine), for beta-blockers from aHR = 0.55 (95%CI = 0.48-0.63) (clozapine) to aHR = 0.76 (95%CI = 0.59-0.99) (perphenazine-LAI). The decreased risk of discontinuation associated with antipsychotic use somewhat varied between age strata. Sensitivity analyses confirmed main findings.</AbstractText>
          <AbstractText Label="DISCUSSION">In this national database within-subject design study, current antipsychotic use was associated with substantially decreased risk of discontinuation of statins, anti-diabetics, antihypertensives, and beta-blockers, which might explain reduced cardiovascular mortality observed with antipsychotics in people with schizophrenia.</AbstractText>
          <CopyrightInformation>© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Solmi</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-4877-7233</Identifier>
            <AffiliationInfo>
              <Affiliation>Neurosciences Department, University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Padua Neurosciences Center, University of Padua, Padua, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tiihonen</LastName>
            <ForeName>Jari</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Niuvanniemi Hospital, Kuopio,Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, &amp; Stockholm Health Care Services, Region Stockholm, Stockholm,Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lähteenvuo</LastName>
            <ForeName>Markku</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-7244-145X</Identifier>
            <AffiliationInfo>
              <Affiliation>Niuvanniemi Hospital, Kuopio,Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanskanen</LastName>
            <ForeName>Antti</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Niuvanniemi Hospital, Kuopio,Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Correll</LastName>
            <ForeName>Christoph U</ForeName>
            <Initials>CU</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité University Medicine Berlin, Berlin,Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taipale</LastName>
            <ForeName>Heidi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Niuvanniemi Hospital, Kuopio,Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm,Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, University of Eastern Finland, Kuopio,Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Schizophr Bull</MedlineTA>
        <NlmUniqueID>0236760</NlmUniqueID>
        <ISSNLinking>0586-7614</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName>
          <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008659" MajorTopicYN="N">Metabolic Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">adherence</Keyword>
        <Keyword MajorTopicYN="Y">cardiovascular disease</Keyword>
        <Keyword MajorTopicYN="Y">cholesterol</Keyword>
        <Keyword MajorTopicYN="Y">diabetes</Keyword>
        <Keyword MajorTopicYN="Y">physical health</Keyword>
        <Keyword MajorTopicYN="Y">psychiatry</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>7</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34286338</ArticleId>
        <ArticleId IdType="pmc">PMC8781351</ArticleId>
        <ArticleId IdType="doi">10.1093/schbul/sbab087</ArticleId>
        <ArticleId IdType="pii">6324813</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28237639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pan YJ, Yeh LL, Chan HY, Chang CK. Excess mortality and shortened life expectancy in people with major mental illnesses in Taiwan. Epidemiol Psychiatr Sci. 2020;29:e156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7443795</ArticleId>
            <ArticleId IdType="pubmed">32792024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ran MS, Xiao Y, Fazel S, et al. . 
Mortality and suicide in schizophrenia: 21-year follow-up in rural China. BJPsych Open. 2020;6(6):e121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7576648</ArticleId>
            <ArticleId IdType="pubmed">33054894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatr Scand. 2018;138(6):492–499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29900527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vancampfort D, Stubbs B, Mitchell AJ, et al. . 
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4592657</ArticleId>
            <ArticleId IdType="pubmed">26407790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vancampfort D, Correll CU, Galling B, et al. . 
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15(2):166–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4911762</ArticleId>
            <ArticleId IdType="pubmed">27265707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Firth J, Solmi M, Wootton RE, et al. . 
A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19(3):360–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7491615</ArticleId>
            <ArticleId IdType="pubmed">32931092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Firth J, Siddiqi N, Koyanagi A, et al. . 
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6(8):675–712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31324560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Solmi M, Veronese N, et al. . 
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5428179</ArticleId>
            <ArticleId IdType="pubmed">28498599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solmi M, Murru A, Pacchiarotti I, et al. . 
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5499790</ArticleId>
            <ArticleId IdType="pubmed">28721057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011;17(2):97–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3053585</ArticleId>
            <ArticleId IdType="pubmed">21185230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22009159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pillinger T, McCutcheon RA, Vano L, et al. . 
Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7029416</ArticleId>
            <ArticleId IdType="pubmed">31860457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19(1):61–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6953552</ArticleId>
            <ArticleId IdType="pubmed">31922669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oh J, Nam H, Park S, Chae JH, Kim TS. Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: a Korean national cohort study. Schizophr Res. 2021;228:417–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33556675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull. 2019;45(2):315–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6403051</ArticleId>
            <ArticleId IdType="pubmed">29697804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taipale H, Mehtälä J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–1387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192491</ArticleId>
            <ArticleId IdType="pubmed">29272458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanskanen A, Taipale H, Koponen M, et al. . 
From prescription drug purchases to drug use periods – a second generation method (PRE2DUP). BMC Med Inform Decis Mak. 2015;15:21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4382934</ArticleId>
            <ArticleId IdType="pubmed">25890003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lichtenstein P, Halldner L, Zetterqvist J, et al. . 
Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3664186</ArticleId>
            <ArticleId IdType="pubmed">23171097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34(2):187–202. doi:10.1111/j.2517-6161.1972.tb00899.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2517-6161.1972.tb00899.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Allison P.
Fixed Effects Regression Models. SAGE Publications; 2009:160. Available from: https://us.sagepub.com/en-us/nam/fixed-effects-regression-models/book226025</Citation>
        </Reference>
        <Reference>
          <Citation>
Schemper M. Cox analysis of survival data with non-proportional hazard functions. J R Stat Soc Ser D (The Stat). 1992;41(4):455–465.</Citation>
        </Reference>
        <Reference>
          <Citation>
Chowdhury R, Khan H, Heydon E, et al. . 
Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–2948.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23907142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shin S, Song H, Oh SK, Choi KE, Kim H, Jang S. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2013;36(11):1000–1005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23966057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6439552</ArticleId>
            <ArticleId IdType="pubmed">30758506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ho PM, Magid DJ, Shetterly SM, et al. . 
Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18371492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nelson LA, Graham MR, Lindsey CC, Rasu RS. Medication adherence and glycemic control in patients with psychotic disorders in the Veterans Affairs healthcare system. Pharm Pract (Granada). 2011;9(2):57–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3969827</ArticleId>
            <ArticleId IdType="pubmed">24688610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med. 2003;65(1):156–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12554828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kinjo M, Chia-Cheng Lai E, Korhonen MJ, McGill RL, Setoguchi S. Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs. Open Heart. 2017;4(1):e000417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5515136</ArticleId>
            <ArticleId IdType="pubmed">28761670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kane JM, Correll CU. The Role of Clozapine in Treatment-Resistant Schizophrenia. JAMA Psychiatry. 2016;73(3):187–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26841681</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
